peopleimages / iStockphoto.com
9 April 2019Americas
Alnylam and Regeneron unveil RNAi partnership
Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference (RNAi) therapeutics.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Europe
12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Biotechnology
6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Big Pharma
8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Editor's picks
Editor's picks
Europe
12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Biotechnology
6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Big Pharma
8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Europe
12 January 2018 Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.
Biotechnology
6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Big Pharma
8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.